```
> s EB 1089/cn
L1            1 EB 1089/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2002 ACS
RN   134404-52-7  REGISTRY
CN   1,3-Cyclohexanediol,
5-[(2E)-[(1R,3aS,7aR)-1-[(1R,2E,4E)-6-ethyl-6-hydroxy-

1-methyl-2,4-octadienyl]octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-
     4-methylene-, (1R,3S,5Z)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1,3-Cyclohexanediol, 5-[[1-(6-ethyl-6-hydroxy-1-methyl-2,4-

octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene]ethylidene]-4-methylene-
     , [1R-[1.alpha.(1R*,2E,4E),3a.beta.,4E(1R*,3S*,5Z),7a.alpha.]]-
OTHER NAMES:
CN   EB 1089
CN   Seocalcitol
FS   STEREOSEARCH
MF   C30 H46 O3
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAPLUS, DDFU, DRUGNL, DRUGU, DRUGUPDATES,
       EMBASE, IPA, MEDLINE, PHAR, PROMT, TOXCENTER, TOXLIT, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             149 REFERENCES IN FILE CA (1967 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             151 REFERENCES IN FILE CAPLUS (1967 TO DATE)


=> file embase biosis medline caplus uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.90       6.05

FILE 'EMBASE' ENTERED AT 17:45:34 ON 20 FEB 2002
```

COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:45:34 ON 20 FEB 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 17:45:34 ON 20 FEB 2002

FILE 'CAPLUS' ENTERED AT 17:45:34 ON 20 FEB 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 17:45:34 ON 20 FEB 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Vitamin D3 or vitamin D or 134404-52-7/rn or EB 1089
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
'RN' IS NOT A VALID FIELD CODE
L2 97755 VITAMIN D3 OR VITAMIN D OR 134404-52-7/RN OR EB 1089

=> s cancer or carcinoma or sarcoma or malignant or tumor
3 FILES SEARCHED...
L3 3603902 CANCER OR CARCINOMA OR SARCOMA OR MALIGNANT OR TUMOR

=> s l2 and l3
L4 9423 L2 AND L3

=> s anti inflammatory or inflammation or pain or analgesic or analgesia
L5 1166306 ANTI INFLAMMATORY OR INFLAMMATION OR PAIN OR ANALGESIC OR
ANALGE
SIA

=> s l4 and l5
L6 1191 L4 AND L5

=> s naproxen or NSAID? or asprin or salicylat
L7 43258 NAPROXEN OR NSAID? OR ASPRIN OR SALICYLAT

=> s l6 and l7
L8 90 L6 AND L7

=> s asprin or naproxen
L9 22123 ASPRIN OR NAPROXEN

=> s l8 and l9
L10 70 L8 AND L9

=> s l10 nd py<2000
MISSING OPERATOR L10 ND
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l10 and py<2000
2 FILES SEARCHED...
L11 41 L10 AND PY<2000

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12 38 DUP REM L11 (3 DUPLICATES REMOVED)

=> d l12 1-38 ab bib

L12 ANSWER 1 OF 38 USPATFULL
AB N-L-.alpha.-Aspartyl-L-phenylalanine 1-methyl ester (APM) and its derivatives have been found to effect disease regression in osteoarthritis, osteoporosis, and rheumatoid arthritis. APM performs as a TNF-.alpha. antagonist as well as an antipyretic agent.
AN 2001:10929 USPATFULL
TI Use of N-L-.alpha.-aspartyl-L-phenylalanine 1-methyl ester and its derivatives in disease regression
IN Edmundson, Allen B., Edmond, OK, United States
Manion, Carl V., Oklahoma City, OK, United States
PA Oklahoma Medical Research Foundation, Oklahoma City, OK, United States (U.S. corporation)
PI US 6177467 B1 20010123
WO 9813062 19980402 <--
AI US 1999-269420 19990326 (9)
WO 1997-US17357 19970926
19990326 PCT 371 date
19990326 PCT 102(e) date
PRAI US 1996-26720 19960926 (60)
US 1997-44831 19970425 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Sidley & Austin
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 22 Drawing Figure(s); 22 Drawing Page(s)
LN.CNT 794
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 2 OF 38 USPATFULL
AB A process for making a phosphoester polymer comprising the recurring monomeric units of formula I: ##STR1## wherein: X is --O-- or --NR"--, where R" is H or alkyl;

L is a divalent organic moiety;

R' is H, alkyl, alkoxy, aryl, aryloxy, heterocyclic, or heterocycloxy; and

n is between about 25 to 2,000,

is described. The process comprises the steps of:

(a) polymerizing in the presence of a solvent p moles of a di-XH compound having formula II:

H--X--L--X--H II

wherein X and L are as defined above, with q moles, where p.apprxeq.q, of a phosphorodihalo compound to form a polymer of formula I, wherein n is about 12 to 1000, having a first molecular weight Mw.sub.1, wherein the solvent is present in an amount greater than about 5 ml of solvent per gram of compound of formula II;

(b) removing at least about 25% of the solvent to form a more concentrated reaction mixture; and

(c) further polymerizing the concentrated reaction mixture for an additional time sufficient to produce a polymer of formula I wherein n is between about 25 and 2,000, the polymer having a second molecular weight Mw.sub.2, which is significantly higher than Mw.sub.1.

AN 1999:170710 USPATFULL
TI Two-stage solution polymerization of high molecular weight poly(phosphoesters)
IN Zhao, Zhong, Ellicott City, MD, United States
Mao, Hai-quan, Towson, MD, United States
Leong, Kam W., Ellicott City, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6008318 19991228 <--
AI US 1998-98620 19980617 (9)
RLI Continuation of Ser. No. US 1997-877624, filed on 18 Jun 1997, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Truong, Duc
LREP Howrey & Simon
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 4 Drawing Figure(s); 4 Drawing Page(s)
LN.CNT 1244
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 3 OF 38 USPATFULL
AB The instant disclosure relates to cochleates comprising a) a biologically relevant molecule component b) a negatively charged lipid component, and c) a divalent cation component. The cochleate has an extended shelf life, even in a desiccated state. Advantageously, the cochleate can be ingested. The biologically relevant molecule can be a topical application and an in vitro treatment, a polypeptide a drug, a nutrient, or a flavor.
AN 1999:155701 USPATFULL
TI Cochleate delivery vehicles
IN Gould-Fogerite, Susan, Annandale, NJ, United States
Mannino, Raphael James, Annandale, NJ, United States
PA Albany Medical College, Albany, NY, United States (U.S. corporation)
University of Medicine and Dentistry of New Jersey, Newark, NJ, United States (U.S. corporation)
PI US 5994318 19991130 <--
AI US 1997-803662 19970221 (8)
RLI Continuation-in-part of Ser. No. WO 1996-US1704, filed on 22 Feb 1996 which is a continuation-in-part of Ser. No. US 1995-394170, filed on 22 Feb 1995, now patented, Pat. No. US 5840707 which is a continuation-in-part of Ser. No. US 1993-130986, filed on 4 Oct 1993, now patented, Pat. No. US 5643574
DT Utility
FS Granted
EXNAM Primary Examiner: Campell, Bruce R.; Assistant Examiner: Nguyen, Dave Trong
LREP Sughrue, Mion, Zinn, Macpeak & Seas, PLLC
CLMN Number of Claims: 59
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1541

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 4 OF 38 USPATFULL
AB The invention provides 1.alpha.-hydroxyvitamin D compounds in which the C-25 or equivalent position of the C-17 side chain has a double bond and
method for their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders.
AN 1999:132802 USPATFULL
TI 1 .alpha.-hydroxy-25-ene-**vitamin D**, analogs and uses thereof
IN Bishop, Charles W., 5 LaPointe Ter., Madison, WI, United States 53719
Knutson, Joyce C., 24 N. Prospect Ave., Madison, WI, United States 53705
Strugnell, Stephen, 2622 Dahle St., Madison, WI, United States 53704
PI US 5972917 19991026 <--
AI US 1998-87439 19980529 (9)
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Michael Best & Friedrich LLP, Welch, Teresa J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
LN.CNT 1256
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 5 OF 38 USPATFULL
AB A process for making a high molecular weight poly(phosphoester) composition comprising:

(i) a biologically active substance; and

(ii) a poly(phosphoester) with the recurring monomeric units: ##STR1## wherein X is --O-- or --NR"--, where R" is H or alkyl; L is a divalent organic moiety, with the proviso that L cannot have the formula
##STR2##
R' is H, alkyl, alkoxy, aryl, aryloxy, heterocyclic, or heterocycloxy; and n is from about 25 to 2000,

is described. The process comprises the steps of:

(a) substantially dissolving p moles of a di--XH compound in a solvent comprising more than 75% toluene at a first temperature between about -75.degree. C. and +60.degree. C. to form a reaction mixture;

(b) while maintaining the reaction mixture at the first temperature, adding q moles, where p.apprxeq.q, of a phosphorodihalo compound;

(c) gradually increasing said first temperature at a rate of less than about 1.5.degree. C. per minute as necessary to achieve a second temperature between about 0.degree. C. and 150.degree. C., and mixing the reaction mixture at the second temperature to form the polymer of formula I; and

(d) isolating the polymer of formula I.

(e) incorporating the biologically active substance into the polymer of

formula I.
AN 1999:110440 USPATFULL
TI Solution polymerization of high molecular weight poly(phosphoesters) in toluene
IN Zhao, Zhong, Towson, MD, United States
PA Guilford Pharmaceuticals Inc., Baltimore, MD, United States (U.S. corporation)
PI US 5952451 19990914 <--
AI US 1998-102813 19980623 (9)
RLI Continuation-in-part of Ser. No. US 1997-884382, filed on 27 Jun 1997
DT Utility
FS Granted
EXNAM Primary Examiner: Mosley, Terressa
LREP Nath & Associates, Nath, Gary M., Drost, Patricia M.
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 1148
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 6 OF 38 USPATFULL
AB The subject invention involves methods and compositions for reducing non-ultraviolet-induced free radical damage in mammals comprising administering to a mammal a composition comprising a safe and effective amount of a compound selected from 2,4-dienoic acid esters of tocopherols and mixtures of such compounds, optionally in combination with chelating agents and/or **anti-inflammatory** agents.
AN 1999:78763 USPATFULL
TI Methods and compositions employing 2,4-dienoic acid esters of tocopherols to prevent or reduce skin damage
IN Bissett, Donald L., Hamilton, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5922758 19990713 <--
AI US 1998-58620 19980409 (9)
RLI Continuation-in-part of Ser. No. US 1997-902868, filed on 30 Jul 1997, now patented, Pat. No. US 5739156, issued on 14 Apr 1998 which is a continuation of Ser. No. US 1994-309838, filed on 21 Sep 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Jordan, Kimberly
LREP Henderson, Loretta J., Graff, IV, Milton B., Howell, John M.
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 7 OF 38 USPATFULL
AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., **NSAIDs**). Invention conjugates provide a new class of pharmacologically active agents (e.g., **anti-inflammatory** agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified

pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

AN 1999:72602 USPATFULL
TI Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
IN Lai, Ching-San, Encinitas, CA, United States
PA Medinox, Inc., San Diego, CA, United States (U.S. corporation)
PI US 5916910 19990629 <--
AI US 1997-869158 19970604 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Davis, Zinna Northington
LREP Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich
CLMN Number of Claims: 27
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1842
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 8 OF 38 USPATFULL
AB A composition is disclosed comprising a water-insoluble or slightly water-soluble compound and a branched cyclodextrin-carboxylic acid. The branched cyclodextrin-carboxylic acid significantly increases the water-solubility of the compound. Also disclosed is a method of enhancing water-solubility of the compound.
AN 1998:147591 USPATFULL
TI Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
IN Uda, Yoshiaki, Yonago, Japan
Yamauchi, Takako, Takarazuka, Japan
Nakagawa, Yasushi, Kawanishi, Japan
Ishiguro, Toshihiro, Toyono-gun, Japan
Oka, Masahide, Kawanishi, Japan
Yamaguchi, Takamasa, Kobe, Japan
Nogami, Ikuo, Nagaokakyo, Japan
PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
PI US 5840881 19981124 <--
AI US 1995-437227 19950508 (8)
RLI Continuation-in-part of Ser. No. US 1994-353326, filed on 5 Dec 1994, now abandoned And Ser. No. US 1993-152122, filed on 15 Nov 1993, now patented, Pat. No. US 5434061
PRAI JP 1992-318807 19921127
JP 1993-50652 19930311
JP 1993-173121 19930713
JP 1993-305597 19931206
DT Utility
FS Granted
EXNAM Primary Examiner: Wilson, James O.
LREP Wenderoth, Lind & Ponack, L.L.P.
CLMN Number of Claims: 6
ECL Exemplary Claim: 1
DRWN 6 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 9 OF 38 USPATFULL
AB The invention provides a method for preventing and alleviating the harmful biological effects of secretion of chemicals from mast cells in the organism of mammals which leads to clinical conditions namely allergy, asthma, arthritis, dermatitis, interstitial cystitis, inflammatory and irritable bowel disease, migraines, multiple sclerosis, scleroderma or systemic sclerosis, ulcerative disease of the gastro-intestinal tract and urticaria, among others. The method consists in administering to said mammals and especially to human beings an amount, effective against said conditions, of an H.sub.3 receptor agonist which has inhibitory activity of neurohormonal activation of mast cell secretion.
AN 1998:124583 USPATFULL
TI H.sub.3 -receptor agonists as therapeutic agents
IN Theoharides, Theoharis C., 14 Parkman St., #2, Brookline, MA, United States 02146
PI US 5821259 19981013 <--
AI US 1995-524023 19950906 (8)
RLI Continuation of Ser. No. US 1994-284041, filed on 1 Aug 1994, now abandoned which is a continuation of Ser. No. US 1993-37697, filed on 24 Mar 1993, now abandoned which is a continuation of Ser. No. US 1991-790343, filed on 12 Nov 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: MacMillan, Keith D.
LREP Foley & Lardner
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 10 OF 38 USPATFULL
AB Gas and gaseous precursor filled microspheres, and foams thereof, provide novel topical and subcutaneous delivery vehicles for various active ingredients, including drugs and cosmetics.
AN 1998:33606 USPATFULL
TI Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
IN Unger, Evan C., Tucson, AZ, United States
Matsunaga, Terry O., Tucson, AZ, United States
Yellowhair, David, Tucson, AZ, United States
PA ImaRx Pharmaceutical Corp., Tucson, AZ, United States (U.S. corporation)
PI US 5733572 19980331 <--
AI US 1994-346426 19941129 (8)
RLI Continuation-in-part of Ser. No. US 1994-307305, filed on 16 Sep 1994 Ser. No. Ser. No. US 1993-159687, filed on 30 Nov 1993, now patented, Pat. No. US 5585112 Ser. No. Ser. No. US 1993-160232, filed on 30 Nov 1993, now patented, Pat. No. US 5542935 And Ser. No. US 1993-159674, filed on 30 Nov 1993, now abandoned , said Ser. No. US -159687 Ser. No. Ser. No. US -160232 And Ser. No. US -159674 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1993-76239, filed on 11 Jun 1993, now patented, Pat. No. US 5469854 And Ser. No. US 1993-76250, filed on 11 Jun 1993, now patented, Pat. No. US 5580575 , said Ser. No. US -76239 And Ser. No. US -76250 , each Ser. No. US - which is a

continuation-in-part of Ser. No. US 1991-717084, filed on 18 Jun 1991, now patented, Pat. No. US 5228446 And Ser. No. US 1991-716899, filed on 18 Jun 1991, now abandoned , said Ser. No. US -717084 And Ser. No. US -716899 , each Ser. No. US - which is a continuation-in-part of Ser. No. US 1990-569828, filed on 20 Aug 1990, now patented, Pat. No. US 5088499 which is a continuation-in-part of Ser. No. US 1989-455707, filed on 22 Dec 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Kishore, Gollamudi S.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 60
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 4174
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 11 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising a radical scavenging agent and an **anti-inflammatory** agent which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of a radical scavenging agent, an **anti-inflammatory** agent, and a sunscreen are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.
AN 1998:6772 USPATFULL
TI Compositions comprising a radical scavenging compound and an **anti-inflammatory** agent
IN Bissett, Donald Lynn, Hamilton, OH, United States
Bush, Rodney Dean, Cincinnati, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5709847 19980120 <--
AI US 1996-744891 19961108 (8)
RLI Continuation of Ser. No. US 1990-543945, filed on 26 Jun 1990, now abandoned which is a division of Ser. No. US 1989-346435, filed on 26 Jun 1989, now patented, Pat. No. US 4954332, issued on 4 Sep 1990 which is a division of Ser. No. US 1987-112575, filed on 22 Oct 1987, now patented, Pat. No. US 4847017, issued on 11 Jul 1989
DT Utility
FS Granted
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Graff, IV, Milton B., Howell, John M., Henderson, Loretta J.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2065
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 12 OF 38 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AB Colorectal **cancer** is the fourth commonest form of **cancer** in men with 678 000 estimated new cases per year worldwide, representing 8.9% of all new **cancers**. The disease is most frequent in Occidental countries and particularly so in North America, Australia, New Zealand, and parts of Europe. Prospects for colorectal **cancer** control are bright and a number of possible approaches could prove fruitful. Among these, pharmaceutical measures seem to be valid and

logical approaches to the prevention of colorectal **cancer** and diminishing its impact. Such approaches could concentrate in primary prevention in at-risk subjects or be applied in altering the course of precursor or established disease. Treatments used must fulfil basic requirements of biological plausibility and safety in continued use in large numbers of subjects. Those available include vitamins and minerals, and other drugs with potential as antioxidants, immune modulators or promoters of cell differentiation or apoptosis. Of the various regimens suggested, vitamin A supplementation may even predispose to adverse outcomes, and antioxidant vitamins in general have no coherent body of evidence to support their use. N-acetylcysteine and ursodeoxycholic acid have promising characteristics but there are as yet no clinical data to support the use of the former in gut epithelial **cancer**, and formal dose ranging studies must be carried out before the latter is submitted to large scale trial. Folate shows promising characteristics but

non-steroidal **anti-inflammatory** drugs and **vitamin D** seem the most promising agents. Both seem to reduce the incidence of disease, and to reduce growth rates and/or induce differentiation or apoptosis in gut epithelial **cancer** cells. Both are also well understood pharmacologically. They may be preferred to newer selective compounds in the same class until these newer compounds are confirmed as safe for widespread long term use.

AN 1998339845 EMBASE
TI Chemoprevention of colorectal **cancer**.
AU Langman M.; Boyle P.
CS M. Langman, Department of Medicine, Queen Elizabeth Hospital, Birmingham B15 2TH, United Kingdom
SO Gut, (1998) 43/4 (578-585).
Refs: 118
ISSN: 0017-5749 CODEN: GUTTAK
CY United Kingdom
DT Journal; General Review
FS 037 Drug Literature Index
048 Gastroenterology
LA English
SL English

L12 ANSWER 13 OF 38 USPATFULL
AB The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for the purposes described above.
AN 97:78464 USPATFULL
TI Method of preventing bone loss
IN Scolnick, Edward M., Wynnewood, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5663195 19970902 <--
AI US 1996-646604 19960508 (8)
RLI Continuation of Ser. No. US 1994-325759, filed on 19 Oct 1994, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Panzer, Curtis C., Rose, David L.
CLMN Number of Claims: 15

ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 14 OF 38 USPATFULL
AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells. In one embodiment, the therapeutic wound healing composition comprises (a) pymvate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids.

In another embodiment, the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In yet another embodiment, the therapeutic wound healing composition comprises (a) an antioxidant and (b) a mixture

of saturated and unsaturated fatty adds. In still yet another embodiment, the therapeutic wound healing composition comprises (a) lactate, (b) an antioxidant, and (c) a mixture of saturated and unsaturated fatty acids. This invention also pertains to wound healing compositions combined with a medicament which is useful for treating injured mammalian cells to form augmented wound healing compositions such as immunostimulating-wound healing compositions, antiviral-wound healing compositions, antikeratolytic-wound healing compositions, **anti-inflammatory**-wound healing compositions, antifungal-wound healing compositions, acne treating-wound healing compositions, sunscreen-wound healing compositions, dermatological-wound

healing compositions, antihistamine-wound healing compositions, antibacterial-wound healing compositions, and bioadhesive-wound healing compositions. This invention also pertains to wound healing compositions

combined with a cytotoxic agent to form cytoprotective-wound healing compositions useful for protecting and reducing injury to mammalian cells and to razor cartridges comprising the wound healing compositions.

This invention also pertains to methods for preparing and using the wound healing compositions and the topical and ingestible pharmaceutical

products in which the therapeutic compositions may be used.
AN 97:66160 USPATFULL
TI Therapeutic-wound healing compositions and methods for preparing and using same
IN Martin, Alain, 31 Country Club Dr., Ringoes, NJ, United States 08551
PI US 5652274 19970729 <--
AI US 1995-445813 19950522 (8)
RLI Continuation-in-part of Ser. No. US 1994-187435, filed on 27 Jan 1994, now abandoned which is a continuation of Ser. No. US 1991-798392, filed on 26 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Criares, Theodore J.
LREP Barish, Jean B.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 90 Drawing Figure(s); 77 Drawing Page(s)
LN.CNT 9592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 15 OF 38 USPATFULL
AB The present invention provides a method for aiding healing or preventing
the onset of intestinal wounds or ulcers in a patient. In addition, the present invention provides a method for reducing, or preventing, the gastrointestinal side effects associated with the administration of a nonsteroidal **anti-inflammatory** drug. Pursuant to the present invention, the composition includes a protein source, a carbohydrate source, a fat source, and a specialized vitamin and mineral
profile.
AN 96:108945 USPATFULL
TI Method and composition for treating intestinal wounds or ulcers
IN Leddin, Desmond, Nova Scotia, Canada
PA Dalhousie University, Nova Scotia, Canada (non-U.S. corporation)
PI US 5578576 19961126 <--
AI US 1994-300428 19940902 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Fleisher, Mindy; Assistant Examiner: Degen, Nancy J.
LREP Hill, Steadman & Simpson
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN 12 Drawing Figure(s); 12 Drawing Page(s)
LN.CNT 733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 16 OF 38 USPATFULL
AB The subject invention involves a method for treating hyperproliferative conditions in mammalian epithelial cells comprising administering to the
mammal a composition containing a safe and effective amount of a lysophosphatidic acid compound or derivative having the structure ##STR1## or a cyclic derivative thereof having the structure ##STR2## or
a pharmaceutically acceptable salt thereof, wherein: a) --Y-- is --O-- or --CH.sub.2 --;

b) --Z is --XH, --H or halo;

c) each --X-- is independently --O-- or --S--; and

d) --R is unsubstituted or substituted, saturated or unsaturated, straight or branched chain alkyl having from 11 to about 23 carbon atoms.
AN 96:94569 USPATFULL
TI Methods of using lysophosphatidic acid for treating hyperproliferative conditions
IN Piazza, Gary A., West Chester, OH, United States
Mazur, Adam W., Cincinnati, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5565439 19961015 <--
AI US 1994-334888 19941104 (8)
RLI Continuation of Ser. No. US 1992-980814, filed on 24 Nov 1992, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Dodson, Shelley A.
LREP Howell, John M., Graff, IV, Milton B., Suter, David L.

CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 17 OF 38 USPATFULL
AB A complex material of a hydrophilic polymer-silicate mineral comprising a carboxyl group containing hydrophilic polymer and a water swellable silicate mineral, and having a new absorption spectrum not existing in both starting materials in the IR-ray absorption spectrum within the range of 1000 to 1300 cm.sup.-1, and pharmaceutical and cosmetic compositions comprising same.
AN 96:65327 USPATFULL
TI Hydrophilic polymer-silicate mineral complex material and use thereof
IN Yanaki, Toshio, Yokohama, Japan
Takahashi, Tadahito, Yokohama, Japan
Nagasawa, Yoko, Yokohama, Japan
Yamaguchi, Michihiro, Yokohama, Japan
PA Shiseido Company, Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5538728 19960723 <--
AI US 1993-46840 19930414 (8)
RLI Continuation of Ser. No. US 1991-688513, filed on 12 Jun 1991, now abandoned
PRAI JP 1989-272324 19891019
JP 1990-258542 19900927
JP 1990-258543 19900927
JP 1990-258544 19900927
DT Utility
FS Granted
EXNAM Primary Examiner: Page, Thurman K.; Assistant Examiner: Bawa, Raj
LREP Foley & Lardner
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 9 Drawing Figure(s); 5 Drawing Page(s)
LN.CNT 2126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 18 OF 38 USPATFULL
AB Biodegradable controlled release delivery systems using melt-spun biodegradable polymers as carriers for bio-effecting agents such as pharmaceutical actives are disclosed. Oral dosage forms as well as implants are described.
AN 96:43387 USPATFULL
TI Biodegradable controlled release flash flow melt-spun delivery system
IN Fuisz, Richard C., Great Falls, VA, United States
PA Fuisz Technologies Ltd., Chantilly, VA, United States (U.S. corporation)
PI US 5518730 19960521 <--
AI US 1992-893238 19920603 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Webman, Edward J.
LREP Hoffmann & Baron
CLMN Number of Claims: 28
ECL Exemplary Claim: 1
DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
LN.CNT 1072
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 19 OF 38 USPATFULL
AB The subject invention relates to pharmaceutical compositions comprising a safe and effective amount of a compound having the structure:
##STR1##
wherein n is 3 or 4; each R is independently alkyl or alkoxy; and R' is C.sub.1 C.sub.20 alkyl; and a pharmaceutically-acceptable topical carrier.

The subject invention also relates to methods for preventing damage to skin, without markedly sensitizing the skin, by topically applying a safe and effective amount of such compounds to the skin.
AN 96:14592 USPATFULL
TI Benzoylacetate esters as non-sensitizing chelating photo-protectants
IN Bush, Rodney D., Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5492690 19960220 <--
AI US 1994-205969 19940303 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Chang, Ceila
LREP Henderson, Loretta J., Howell, John M., Suter, David L.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1511
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 20 OF 38 USPATFULL
AB The present invention involves photoprotective compositions which are useful for topical application to prevent damage to skin caused by acute
or chronic exposure to ultraviolet light comprising chelating agents. Also involved are compositions comprising chelating agents together with
anti-inflammatory agents, sunscreening agents, and/or
radical scavenging agents. Methods for using such compositions to prevent damage to skin caused by acute or chronic exposure to ultraviolet light are also involved.
AN 96:9263 USPATFULL
TI Photoprotection compositions comprising chelating agents
IN Bissett, Donald L., Hamilton, OH, United States
Bush, Rodney D., Cincinnati, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5487884 19960130 <--
AI US 1993-86757 19930701 (8)
RLI Continuation of Ser. No. US 1990-619805, filed on 27 Nov 1990, now abandoned which is a continuation of Ser. No. US 1988-251910, filed on 4
Oct 1988, now abandoned which is a continuation-in-part of Ser. No. US 1987-112576, filed on 22 Oct 1987, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, Milton B., Suter, David L., Yetter, Jerry J.
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings

LN.CNT 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 21 OF 38 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 1
AB Interleukin-1 (IL-1) and **tumor** necrosis factor (TNF), two pleiotropic cytokines produced in inflammatory processes, inhibit bone matrix biosynthesis and stimulate prostanoid formation in osteoblasts. In the present study, the importance of prostaglandin formation in IL-1 and TNF-induced inhibition of osteocalcin and type I collagen formation has been examined. In the human osteoblastic cell line MG-63, IL-1.alpha. (10-1000 pg/ml), IL-1.beta. (3-300 pg/ml) and TNF-.alpha. (1-30 ng/ml) stimulated prostaglandin E2 (PGE2) formation and inhibited 1,25(OH)2-**vitamin D3**-induced osteocalcin biosynthesis as well as basal production of type I collagen. Addition of PGE2 or increasing the endogenous formation of PGE2 by treating the cells with arachidonic acid, bradykinin, Lys-bradykinin or des-Arg9-bradykinin, did not affect osteocalcin and type I collagen formation in unstimulated or 1,25(OH)2-**vitamin D3**-stimulated osteoblasts. Four non-steroidal **anti-inflammatory** drugs, indomethacin, flurbiprofen, **naproxen** and meclofenamic acid, inhibited basal, IL-1.beta.- and TNF-.alpha.-stimulated PGE2 formation in the MG-63 cells without affecting IL-1 .beta.- or TNF-.alpha.-induced inhibition of osteocalcin and type I collagen formation. In isolated, non-transformed, human osteoblast-like cells, IL-1.beta. and TNF-.alpha. stimulated PGE2 formation and concomitantly inhibited 1,25(OH)2-**vitamin D3** -stimulated osteocalcin biosynthesis, without affecting type I collagen formation. In these cells, indomethacin and flurbiprofen abolished the effects of IL-1.beta. and TNF-.alpha. on prostaglandin formation without affecting the inhibitory effects of the cytokines on osteocalcin biosynthesis. These data show that IL-1 and TNF inhibit osteocalcin and type I collagen formation in osteoblasts independently of prostaglandin biosynthesis and that non-steroidal antiinflammatory drugs do not affect the effects of IL-1 and TNF on bone matrix biosynthesis.
AN 96299857 EMBASE
DN 1996299857
TI Cytokine-induced inhibition of bone matrix proteins is not mediated by prostaglandins.
AU Rosenquist J.B.; Ohlin A.; Lerner U.H.
CS Department of Oral Cell Biology, University of Umea,S-901 87 Umea, Sweden
SO Inflammation Research, (1996) 45/9 (457-463).
ISSN: 1023-3830 CODEN: INREFB
CY Switzerland
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
031 Arthritis and Rheumatism
037 Drug Literature Index
LA English
SL English

L12 ANSWER 22 OF 38 USPATFULL
AB The present invention involves photoprotective compositions which are useful for topical application to prevent damage to skin caused by acute or chronic exposure to ultraviolet light comprising chelating agents having the structure: ##STR1## wherein each --R.sup.1 is independently selected from the group consisting of alkyl, aryl, heteroaryl and heterocycle, or the --R.sup.1 's are covalently bonded together to form a cyclic alkyl or heterocyclic ring; --R.sup.2 and --R.sup.3 are --OR.sup.4, in which case there is no bond or a polar bond between

--R.sup.2 and the nitrogen covalently bonded to --R.sup.3, each --R.sup.4 being independently selected from the group consisting of hydrogen, alkyl and aryl, except that both --R.sup.4 's are not methyl when both --R.sup.1 's are furyl; or --R.sup.2 is --O-- and is covalently bonded to the nitrogen which is covalently bonded to --R.sup.3, and --R.sup.3 is --O-- (there being a + charge on the nitrogen to which it is bonded) or nil;

wherein the .alpha.-diamine compounds consist essentially of compounds wherein .dbd.NR.sup.2 and .dbd.NR.sup.3 are in amphi configuration when both --R.sup.2 and --R.sup.3 are --OH, and when both --R.sup.1 's are furyl or the --R.sup.1 's are covalently bonded together to form a cyclohexanedione structure.

Methods for using such compositions to prevent damage to skin caused by acute or chronic exposure to ultraviolet light are also involved.

AN 95:97047 USPATFULL
TI Chelator compositions comprising .alpha.-diamine compounds
IN Bush, Rodney D., Fairfield, OH, United States
Bissett, Donald L., Hamilton, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5462963 19951031 <--
AI US 1991-739933 19910802 (7)
RLI Continuation-in-part of Ser. No. US 1990-514892, filed on 26 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Raymond, Richard L.
LREP Graff, Milton B., Yetter, Jerry J., Howell, John M.
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 23 OF 38 USPATFULL
AB The subject invention relates to pharmaceutical compositions comprising a safe and effective amount of a compound having the structure:
##STR1##
wherein each R is alkyl or hydrogen, at least two being alkyl; R' is hydrogen, alkyl or aryl; R" is alkyl or halo; and each X is independently oxygen or sulfur; and a pharmaceutically-acceptable carrier. The subject invention also relates to methods for preventing damage to skin by topically applying a safe and effective amount of such
compounds to the skin.
AN 95:71404 USPATFULL
TI Substituted phenyl-1,3-diketones as protectants against skin damage
IN Bush, Rodney D., Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5439954 19950808 <--
AI US 1991-776506 19911011 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Howell, John M., Graff, IV, Milton B., Yetter, Jerry J.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 1712
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 24 OF 38 USPATFULL
AB Disclosed are photoprotective compositions comprising a radical scavenging agent and an **anti-inflammatory** agent which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of a radical scavenging agent, an **anti-inflammatory** agent, and a sunscreen are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.
AN 95:7681 USPATFULL
TI Photoprotection compositions comprising a radical scavenging compound and an **anti-inflammatory** agent
IN Bissett, Donald L., Hamilton, OH, United States
Bush, Rodney D., Cincinnati, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5384115 19950124 <--
AI US 1993-110028 19930820 (8)
RLI Division of Ser. No. US 1990-543945, filed on 26 Jun 1990 which is a division of Ser. No. US 1989-346435, filed on 26 Jun 1989, now patented,
Pat. No. US 4954332, issued on 4 Sep 1990 which is a division of Ser. No. US 1987-112575, filed on 22 Oct 1987, now patented, Pat. No. US 4847017, issued on 11 Jul 1989
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Howell, John M., Graff, IV, Milton B.
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2011
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 25 OF 38 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.
AN 95089998 EMBASE
DN 1995089998
TI Arthritis in children.
AU Southwood T.R.
CS Department of Rheumatology, University of Birmingham,Birmingham, United Kingdom
SO British Medical Journal, (1995) 310/6981 (728-732).
ISSN: 0959-8146 CODEN: BMJOAE
CY United Kingdom
DT Journal; Article
FS 007 Pediatrics and Pediatric Surgery
031 Arthritis and Rheumatism
037 Drug Literature Index
038 Adverse Reactions Titles
LA English

L12 ANSWER 26 OF 38 USPATFULL
AB The present invention involves photoprotective compositions which are useful for topical application to prevent damage to skin caused by acute

or chronic exposure to ultraviolet light comprising chelating agents having the formula ##STR1## wherein --R.sup.1 and --R.sup.2 are independently selected from the group consisting of alkyl, aryl, and heteroaryl, or R.sup.1 and R.sup.2 may be covalently bonded together to form a cyclic alkyl; --M is selected from the group consisting of =0, =S, --SR.sup.4 and --OR.sup.4 (when --M is --OR.sup.4 or --SR.sup.4, there is a hydrogen bonded to the carbon to which --M is bonded); --R.sup.4 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl; --R.sup.3 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl; --R.sup.6 is selected from the group consisting of hydrogen alkyl, aryl and heteroaryl; and i is selected from the group consisting of one and zero. Methods for using such compositions to prevent damage to skin caused by acute or chronic exposure to ultraviolet light are al so involved.

AN 94:99673 USPATFULL
TI Chelator compositions comprising oxime compounds
IN Bush, Rodney D., Fairfield, OH, United States
Bissett, Donald L., Hamilton, OH, United States
Chatterjee, Ranjit, Cincinnati, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5364617 19941115 <--
AI US 1992-973597 19921109 (7)
RLI Continuation of Ser. No. US 1991-657847, filed on 25 Feb 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-514998, filed on 26 Apr 1990, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Richter, Johann; Assistant Examiner: Scalzo, Catherine S. Kilby
LREP Simon, Soma G., Graff, IV, Milton B., Suter, David L.
CLMN Number of Claims: 17
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 27 OF 38 EMBASE COPYRIGHT 2002 ELSEVIER SCI. B.V.DUPLICATE 2
AB Data from several laboratories suggest a role for a variety of cytokines in the process of bone resorption. SK and F 86002 [5-(4-pyridyl)-6(4-fluorophenyl)-2,3-dihydroimidazo(2,1-b)thiazole], a potent cytokine-suppressive **anti-inflammatory** agent, has been shown to inhibit cyclooxygenase (CO) and 5-lipoxygenase (LO) activity and to inhibit the production of cytokines both in vitro and in vivo. In the present study, SK and F 86002 inhibited fetal rat long bone (FRLB) resorption induced by parathyroid hormone (PTH), 1,25-dihydroxy-**vitamin D3**, **tumor** necrosis factor alpha, and Escherichia coli lipopolysaccharide in a dose-dependent (IC50 of 0.5-1 .mu.M) and reversible manner. Under identical conditions, selective CO inhibitors (indomethacin, ibuprofen, **naproxen**) and 5-LO inhibitors (phenidone, SK and F 107649) were inactive. Analogs of SK and F 86002, which are dual CO/LO inhibitors devoid of cytokine inhibitory activity (SK and F 81114 and SK and F 86055), also failed to significantly inhibit PTH-induced FRLB resorption. Analogs of SK and F 86002, which retain cytokine inhibitory activity (SK and F 104493 and SK and F 105561),

inhibit bone resorption. These data indicate that the observed inhibition of bone resorption by compounds of this class correlates with their cytokine suppressive activity.
AN 94250758 EMBASE
DN 1994250758
TI Cytokine suppressive **anti-inflammatory** compounds inhibit bone resorption in vitro.
AU Votta B.J.; Bertolini D.R.
CS Bone Biology Unit, Department of Cellular Biochemistry, SmithKline Beecham Pharmaceuticals, P.O. Box 1539,King of Prussia, PA 19406, United States
SO Bone, (1994) 15/5 (533-538).
ISSN: 8756-3282 CODEN: BONEDL
CY United States
DT Journal; Article
FS 003 Endocrinology
026 Immunology, Serology and Transplantation
029 Clinical Biochemistry
033 Orthopedic Surgery
037 Drug Literature Index
LA English
SL English

L12 ANSWER 28 OF 38 USPATFULL
AB Ultraviolet radiation induced erythema is prevented or treated in a human mammal in need of such prevention or treatment, i.e., a mammal suffering from or seeking to avoid sunburn, by topically administering thereto a unit dosage erythema-preventing or treating effective amount of the S(+) ibuprofen enantiomer, said enantiomer being substantially free of its R(-) ibuprofen antipode.
AN 92:25380 USPATFULL
TI Prevention or treatment of sunburn using the S(+) isomer of ibuprofen
IN Sunshine, Abraham, New York, NY, United States
Laska, Eugene M., Larchmont, NY, United States
PA Sterling Drug, Inc., New York, NY, United States (U.S. corporation)
PI US 5100918 19920331 <--
AI US 1990-593784 19901005 (7)
RLI Continuation-in-part of Ser. No. US 1989-356850, filed on 25 May 1989, now patented, Pat. No. US 4980375 which is a continuation-in-part of Ser. No. US 1987-71914, filed on 10 Jul 1987, now patented, Pat. No. US 4851444
DT Utility
FS Granted
EXNAM Primary Examiner: Friedman, S. J.
LREP Burns, Doane, Swecker & Mathis
CLMN Number of Claims: 54
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 963
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 29 OF 38 USPATFULL
AB A novel and effective treatment of psoriatic arthritis is provided using biologically active forms of **vitamin D** analogues and metabolites, and preferrably 1,25-dihydroxy **vitamin D** .sub.3. The administration of **vitamin D** analogues and metabolites may be made orally, topically, or parenterally. Substitive improvements in both the arthritic condition and skin lesions

result after approximately two month's treatment when effective dosages are provided and maintained.
AN 92:23183 USPATFULL
TI Method for therapeutically treating psoriatic arthritis using **vitamin D** analogues and metabolites
IN Gilbert, Lawrence, Hingham, MA, United States
Holick, Michael F., Sudbury, MA, United States
PA Trustees of Boston University, Boston, MA, United States (U.S. corporation)
PI US 5098899 19920324 <--
AI US 1990-627901 19901214 (7)
RLI Continuation of Ser. No. US 1989-320028, filed on 6 Mar 1989, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Pal, Asok
LREP Prashker, David
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 462
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 30 OF 38 USPATFULL
AB Disclosed are topical compositions comprising sorbohydroxamic acid with a radical scavenging compound which prevent damage to skin caused UV radiation. Also disclosed is a method for using these compositions topically, to prevent damage to skin caused by UV radiation exposure.
AN 91:64670 USPATFULL
TI Photoprotection compositions and methods comprising sorbohydroxamic acid
IN Chatterjee, Ranjit U., Fairfield, OH, United States
Kirchner, Stephen J., Madison, CT, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 5039513 19910813 <--
AI US 1989-398808 19890825 (7)
RLI Division of Ser. No. US 1987-112577, filed on 22 Oct 1987, now patented,
Pat. No. US 4869897
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 31 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising tocopherol sorbate and an **anti-inflammatory** agent which are useful for
topical application to prevent damage to skin caused by acute or chronic
UV exposure. Combinations of tocopherol sorbate, an **anti-inflammatory** agent, and a sunscreen are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

AN 90:69560 USPATFULL
TI Photoprotection compositions comprising tocopherol sorbate and an **anti-inflammatory** agent
IN Bissett, Donald L., Hamilton, OH, United States
Bush, Rodney D., Cincinnati, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4954332 19900904 <--
AI US 1989-346435 19890626 (7)
RLI Division of Ser. No. US 1987-112575, filed on 22 Oct 1987, now patented,
Pat. No. US 4847071
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 32 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising sorbohydroxamic acid, or pharmaceutically-acceptable salts thereof, and an **anti-inflammatory** agent, which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of sorbohydroxamic acid and an **anti-inflammatory** agent together with tocopherol sorbate and/or sunscreens are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.
AN 90:61231 USPATFULL
TI Photoprotection compositions comprising sorbohydroxamic acid and an **anti-inflammatory** agent
IN Bissett, Donald L., Hamilton, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4946671 19900807 <--
AI US 1989-346046 19890502 (7)
RLI Division of Ser. No. US 1987-112588, filed on 22 Oct 1987, now patented,
Pat. No. US 4847069
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2149
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 33 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising sorbohydroxamic acid, or pharmaceutically-acceptable salts thereof, which are useful for

topical application to prevent damage to skin caused by acute or chronic
UV exposure. Combinations of sorbohydroxamic acid together with tocopherol sorbate and/or sunscreens are also disclosed.

Also disclosed is a method for using these compositions topically, prior
to UV exposure, to prevent damage to skin caused by acute or chronic UV exposure.

AN 89:80613 USPATFULL
TI Photoprotection compositions comprising sorbohydroxamic acid
IN Chatterjee, Ranjit, Fairfield, OH, United States
Kirchner, Stephen J., Madison, CT, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4869897 19890926 <--
AI US 1987-112577 19871022 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 34 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising tocopherol sorbate which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of tocopherol sorbate and sunscreening agents are also disclosed.

Also disclosed is a method for using these compositions topically, to prevent damage to skin caused by acute or chronic UV exposure.

AN 89:56222 USPATFULL
TI Photoprotection compositions comprising tocopherol sorbate
IN Bissett, Donald L., Hamilton, OH, United States
Bush, Rodney D., Cincinnati, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4847072 19890711 <--
AI US 1987-112574 19871022 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Schofer, Joseph L.; Assistant Examiner: Smith, Jeffrey
T.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2063
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 35 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising tocopherol sorbate and an **anti-inflammatory** agent which are useful for
topical application to prevent damage to skin caused by acute or chronic

UV exposure. Combinations of tocopherol sorbate, an **anti-inflammatory** agent, and a sunscreen are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

AN 89:56221 USPATFULL
TI Photoprotection compositions comprising tocopherol sorbate and an **anti-inflammatory** agent
IN Bissett, Donald L., Hamilton, OH, United States
Bush, Rodney D., Cincinnati, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4847071 19890711 <--
AI US 1987-112575 19871022 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1977
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 36 OF 38 USPATFULL
AB Disclosed are pharmaceutical compositions comprising sorbohydroxamic acid, or pharmaceutically-acceptable salts thereof, and an **anti-inflammatory** agent, which are useful for topical application to prevent damage to skin caused by acute or chronic UV exposure. Combinations of sorbohydroxamic acid and an **anti-inflammatory** agent together with tocopherol sorbate and/or sunscreens are also disclosed.

Also disclosed is a method for using these compositions topically to prevent damage to skin caused by acute or chronic UV exposure.

AN 89:56219 USPATFULL
TI Photoprotection compositions comprising sorbohydroxamic acid and an **anti-inflammatory** agent
IN Bissett, Donald Lynn, Hamilton, OH, United States
Chatterjee, Ranjit, Fairfield, OH, United States
PA The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)
PI US 4847069 19890711 <--
AI US 1987-112588 19871022 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Ore, Dale R.
LREP Graff, IV, Milton B., Hatfield, Gretchen R., Goldstein, Steven J.
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 37 OF 38 USPATFULL
AB An improvement in a method to conjugate a protein which must resist denaturation with a variable component using a carbodiimide condensing agent utilizes a polar aprotic solvent as the medium for condensation. This improvement results in shorter reaction times and improved coupling

efficiency.
AN 89:51968 USPATFULL
TI Anhydrous enhanced coupling of proteins
IN Levy, Julia G., Vancouver B. C., Canada
Liu, Daniel, Vancouver B. C., Canada
PA University of British Columbia, Vancouver, Canada (non-U.S. corporation)
PI US 4843147 19890627 <--
AI US 1988-248267 19880921 (7)
RLI Continuation of Ser. No. US 1986-927847, filed on 6 Nov 1986, now abandoned
DT Utility
FS Granted
EXNAM Primary Examiner: Moskowitz, Margaret; Assistant Examiner: Kushan, Jeff P.
LREP Irell & Manella
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 516
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L12 ANSWER 38 OF 38 USPATFULL
AB A method for modifying the balance between bone production and bone resorption in a host animal by administration of etodolac to inhibit bone resorption.
AN 87:47059 USPATFULL
TI Inhibition of bone resorption by etodolac
IN Hayward, Marshall A., Lawrenceville, NJ, United States
PA American Home Products Corporation, New York, NY, United States (U.S. corporation)
PI US 4677132 19870630 <--
AI US 1986-839013 19860312 (6)
DT Utility
FS Granted
EXNAM Primary Examiner: Friedman, Stanley J.
LREP Routh, John W.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
LN.CNT 360
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>